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13 C]ureide has been proposed as a noninvasive marker for oro-caecal transit time in adults and children. The present study investigates the handling of lactose [ 13 C]ureide ( 13 C LU) and glucose [ 13 C]ureide ( 13 C GU) by the gastrointestinal tract and describes the metabolic fates of these substrates and describes the extent of tracer excretion by different routes. Study Design and Subjects: Four subjects underwent five studies in which they ingested a test meal plus (1) no substrate, (2) 13 C LU, (3) 13 C GU, (4) 13 C LU after predosing with unlabelled lactose ureide and (5) 13 C LU after predosing with glucose ureide. Subjects were studied at home with at least 1 week between tests and they all completed the study. Breath was analysed for 13 CO 2 recovery and urine was analysed for total 13 C recovery, 13 C urea recovery and 13 C GU recovery. Results: The profiles and extent of tracer recovery in breath and urine were similar when either 13 C GU or 13 C LU was used, suggesting similar handling of these substrates by the gut. 13 C GU was the major 13 C-enriched species recovered in the urine even when 13 C LU was consumed. Predosing with either lactose ureide or glucose ureide increased the rate of appearance of tracer, but did not alter transit times.
Conclusions:
13 C LU is hydrolysed to 13 C GU in the small intestine with the fraction of 13 C GU appearing in the urine probably limited by small intestinal permeability. Either 13 C LU or 13 C GU can be used to measure oro-caecal transit time. Sponsorship: Bell College, Hamilton and Chief Scientist Office, Scotland, UK.
Introduction
Oro-caecal transit time (OCTT) is defined as the period of time taken for a substance that is ingested to reach the caecum. The chemical and physical properties of a meal may affect the time it takes to reach the caecum. Meals of higher energy density slow down gastric emptying (Calbet & Maclean, 1997) and liquids empty from the stomach faster than solids (Santangelo et al, 1998) , although the rate of transit of a solid meal through the small intestine may be independent of the rate of gastric emptying (Read et al, 1982) . Accurate measurement of OCTT has been difficult to achieve noninvasively. Current techniques include scintigraphy (Graff et al, 2000) and the hydrogen (H 2 ) breath test (Bond & Levitt, 1975) . Scintigraphy is considered the 'gold standard' and offers real-time imaging of the progress of the meal through the gut, although it exposes the subject to ionising radiation and is not applicable in many subjects (eg children). The H 2 breath test is noninvasive, although it suffers from poor sensitivity because the test substrate used to generate breath H 2 , through colonic fermentation, induces an osmotic effect that accelerates its transit through the gut (Miller et al, 1997) . Furthermore, the colonic microflora of a significant fraction of the population does not produce breath H 2 upon fermentation (Corazza et al, 1993) .
Common symptoms and signs of gut dysmotility are increased or decreased stool frequency and consistency, intestinal discomfort, bloating or distension (Reynolds, 1996) . However, these clinical features rarely point the clinician to the underlying nature of the problem or its cause. A reliable measure of gut motility would allow the clinician to decide if pharmacological intervention was a suitable course of action to alleviate symptoms. Further-more, a noninvasive test would permit this approach to be readily used in children who present with gastrointestinal complaints.
Glycosyl ureides are the products of the reaction of a reducing sugar and urea in aqueous acid. Lactose ureide, labelled with 13 C on the urea moiety, has been proposed as a new noninvasive marker of OCTT because it resists digestion by small intestinal enzymes and is hydrolysed by bacterial enzymes in the large bowel (Heine et al, 1995) . Bacterial fermentation releases 13 C into the body's bicarbonate pool from where it is excreted in breath as 13 CO 2 . The first sustained rise in breath 13 CO 2 enrichment is a measure of OCTT. As a result of the accuracy and precision of the instruments available to analyse breath 13 CO 2 enrichment, only a small amount of tracer is required to enable its detection in breath, thereby circumventing osmotic effects on OCTT. A number of studies have described the use of lactose [ 13 C]ureide ( 13 C LU) in adults (Wutzke et al, 1997; Geypens et al, 1999; Jackson et al, 1999) and children (Van Den Driessche et al, 2000) although relatively few studies have described its metabolism in the small intestine (Ruemmele et al, 1997) and the colon (Mohr et al, 1999) . This study aimed to investigate the metabolism of 13 C LU and glucose [ 
Materials and methods

Materials
13
C LU, 13 C GU and the analogous unlabelled substrates (LU and GU) were synthesised as described previously (Morrison et al, 2001) . Sugar ureides are the condensation products of a reducing sugar and urea in mild aqueous acid. Their synthesis is simple and avoids the use of toxic chemicals, making them safe for use in clinical practice. The chemical structures of 13 C LU and 13 C GU are shown in Figure 1 , where * denotes the position of 13 C enrichment. All other substrates were purchased from Sigma-Aldrich Company Ltd (Poole, UK).
Subjects and ethical considerations
Four healthy adult subjects took part in the study (two males, two females; Mean age 35(24-47) y; Mean BMI 27(22-32) kg/m 2 ), all of whom had no gastrointestinal problems nor had received antibiotic therapy in the month prior to the study. Each subject gave written informed consent after the aims of the study and the protocols were explained to them. The study was approved by the University of Glasgow ethical committee for nonclinical investigations in human volunteers.
Test meal
The test meal, consisting of cooked porridge oats with milk, contained 12.3 g protein, 81.6 g carbohydrate and 6.1 g fat per 100 g of meal, and had a total energy value of 1.79 MJ per 100 g. Each subject was allowed to choose the size of meal that suited their appetite, and consumed the same size of meal for each test. Generally, the test meal was consumed within a 10-min period and was well tolerated.
Study design
On the 3 days prior to the test day, the subjects followed a diet restricted in foods with higher natural 13 C abundance to minimise variations in basal breath 13 CO 2 (Morrison et al, 2000) . On the day of the test, each subject consumed the test meal with the test dose ( 13 C LU or 13 C GU) sprinkled on top.
Only water was allowed, ad libitum, for the remainder of the day. Porridge was consumed again on day 2 with subsequent reversal to normal dietary intake. Each subject was studied on five occasions. The tests were: Fed baselineFeach subject consumed only the test meal and sampled breath only for the study period.
Test 1: LUBTFeach subject consumed the test meal with 500 mg 13 C LU. Breath and urine were sampled for the study period.
Test 2: LU-induced LUBTFeach subject consumed 5 Â 1 g of unlabelled LU at approximately 3 h intervals over the day, prior to the test. On the test day, each subject consumed the test meal with 500 mg 13 C LU. Breath and urine were sampled for the study period.
Test 3: GUBTFeach subject ingested 290 mg 13 C GU (equimolar to 500 mg 13 C LU) with the test meal. Breath and urine were sampled for the study period. Test 4: GU-induced LUBT'Feach subject consumed 5 Â 580 mg unlabelled GU at approximately 3 h intervals over the day prior to the test. On the test day, subjects consumed 500 mg 13 C LU with the test meal. Breath and urine were sampled over the study period.
Sample collection and analysis
Serial breath samples were collected in duplicate in 12 ml Exetainers s (Labco Limited, High Wycombe, UK) by blowing through a straw until vapour condensed on the bottom of the tube. Samples were collected prior to the test meal (baseline) and at 30-min intervals throughout the day until bedtime. Samples were also collected for a short period on day 2 of the protocol. Urine samples were collected before the test meal and on each occasion that subjects micturated, for a period of 3 days. Total urine volume and time were noted on each occasion, and two 20 ml aliquots from each urine sample were refrigerated immediately and stored at À201C within 24 h until analysis.
Breath samples were analysed by isotope ratio mass spectrometry (IRMS; Preston & McMillan, 1988) . Briefly, exhaled breath was flushed from the Exetainer s by helium carrier gas, water was removed by a perchlorate trap and CO 2 was separated from other gases by gas chromatography. O to the ion beam at mass 45 (Craig, 1957) . Samples were measured against the laboratory's working standard (3% CO 2 in N 2 ; d 13 C ¼ À30.07%), which had been calibrated against the internationally accepted standard for 13 C analysis, PDB (Pee Dee Belemnite,
A method was devised to analyse qualitatively 13 C output in urine. In total, 10 ml of each urine sample from test 2 (LU-induced LUBT) was developed on a TLC plate (Merck Ltd, Poole, UK) using isopropyl alcohol, ethyl acetate and water (45:20:10) as the mobile phase. TLC plates were run in duplicate. Once developed, one TLC plate was sprayed with anisaldehyde/ethanol/sulphuric acid (18:1:1) in order to visualise the components on the plate. Squares of 1 cm were drawn lightly in pencil on the unstained duplicate plate. Each square of silica was scraped off the TLC plate and transferred to a tin capsule (Elemental Microanalysis, Okehampton, UK) and combusted to analyse 13 C enrichment. The mean 13 C enrichment (ppm 13 C) for each square of the TLC plate, across all urine samples for each subject, was calculated. The ratio of fronts (R f ) was calculated for each square (defined as the fraction travelled along the TLC plate relative to the solvent front) to denote its position on the TLC plate. R f values for glucose, GU, lactose, LU and urea were also determined.
Analysis of breath
13 CO 2 and urine 13 C data Breath test data were analysed using a modified version of the curve-fitting techniques developed to analyse gastric emptying breath test curves (Ghoos et al, 1993) . The function fitted to the data is detailed as
The variables a, b and c each describe a facet of the breath test curve; a is the scaling factor related to the amplitude of the peak, b relates to the ascending slope, and c is related to the decay slope. The function was fitted to the data using Microsoft Excel software. The Solver function was used to minimise the differences (root mean square, RMS) between the fitted curve and the raw data by adjusting the variables a, b, c, d and baseline (Motulsky & Ransnas, 1987) . The variable d was introduced to allow the model to fit breath 13 CO 2 , which had delayed appearance as a result of the time taken for the substrate to reach the caecum. The baseline was included as a variable to allow the model to determine basal 13 CO 2 abundance from the data. Some data sets were better fitted (lower RMS) by the sum of two functions (a two-peak model) rather than one (Morrison et al, 1998) . In these cases, the composite model was fitted to the experimental data to find the best fit.
The parameters derived from the fitted curve were OCTT, T max and PDR. OCTT was defined as the time to the appearance of 10% of the maximal enrichment and was calculated using the Goalseek function in Excel. The Goalseek can be used to find the numerical value of an unknown in an equation, given that all other variables are known. In this context, Goalseek finds the time for equation (1) when Y ¼ 0.l Â maximal enrichment, after a, b, c and d have been determined by nonlinear regression. T max was defined as the time from substrate ingestion to the time of maximal breath enrichment and was calculated using
The fraction of tracer recovered in breath per hour (PDR/h) was calculated using PDR=h ¼ VCO 2 Âbreath 13 C enrichment
where, VCO 2 is the CO 2 production rate (estimated to be 300 mmol/m 2 /h; Shreeve et al, 1970) , breath 13 C enrichment is the 13 C enrichment of breath over baseline (ppm excess), mg dose is the amount of substrate administered (mg); MW is the molecular weight of substrate, dose enrichment is the 13 C enrichment of substrate (ppm 13 C), and n is the number of isotopically labelled atoms in the substrate molecule.
Integrating the PDR values over the period of the test gives the cumulative PDR for the breath test (PDR b ). The total fraction of tracer recovered in urine (PDR) u and as 13 C urea was determined from the enrichment of the samples. These calculations are described elsewhere (Morrison et al, 1999) .
Subjects 3 and 4 wore heart-rate monitors throughout tests 3 and 4 in an attempt to gauge true VCO 2 . The heartrate monitor data were individually calibrated for a range of measured VCO 2 data (Slater et al, 2001) . The data for this study suggested that the subjects' physical activity levels (PALs) averaged 1.2 Â basal metabolic rate (BMR) for the period of the study. In addition, many studies correct PDR data using the bicarbonate recovery factor to get a true measure of substrate oxidation because a proportion of any 13 C tracer traversing the bicarbonate pool can be irreversibly sequestrated (Irving et al, 1983) . Previous studies have shown bicarbonate recovery in breath to approximate 70-80% when subjects are at rest (Hoerr et al, 1989) .
Results
Breath
C recovery
During the fed baseline study, there were no obvious trends in the baseline to lower or higher abundance with time, suggesting that this test meal had no effect on basal 13 CO 2 abundance. The mean 13 C abundance was stable for each subject throughout the protocol and varied by less than 75 ppm 13 C. The profiles of 13 C enrichment in breath 13 CO 2 for each subject from each test are shown in Figure 2 , and the parameters calculated from the modelled data are summarised in Figure 3 . The median (95% CI) OCTTS for subjects 1, 2, 3 and 4 across all tests were 8.1(7.1-9.1), 5.5(4.4-6.7), 3.6(2.6-4.7) and 5.8(3.4-8.3), respectively. Predosing with LU (and GU) decreased the time from first appearance to time of maximal enrichment, T max ÀOCTT. There were no differences in breath tracer recovery (PDR b ) after predosing with LU or when 13 C GU was used to assess OCTT compared with 13 C LU or in total breath tracer recovery.
Urinary 13 C recovery
The profiles of 13 C enrichment in urine for each test are shown in Figure 4 and PDR u in Figure 3 . Tracer enrichment was observed in the urine almost immediately and much earlier than tracer appeared in breath. In some cases, an initial early rise in enrichment was observed followed by a second later peak in urinary enrichment. There appeared to be little difference in urinary tracer recovery between 13 C GU and 13 C LU and the patterns of excretion were similar. Urinary 13 C urea accounted for 2% or less of the total output of tracer. The percentages of tracer excreted in the urine of subjects 1, 2, 3 and 4 as 13 C urea were 2, 1, 1 and, 1.5% of total 13 C intake, respectively. 13 C GU was qualitatively identified in the urine of all subjects after the ingestion of 13 C LU (test 2). Enrichment was found mainly at an R f corresponding to 13 C GU (R f ¼ 0.45). No enrichment was observed from the TLC plate at R f corresponding to 13 C LU (R f ¼ 0.21), with only minor enrichment observed at R f corresponding to 13 C urea (R f ¼ 0.80).
Correction factors
The data from the heart-rate monitors illustrated clearly that the subjects were not at true resting metabolic rate throughout the period of the test. This suggests that estimated VCO 2 (300 mmol/m 2 /h) at BMR was not an accurate estimate of CO 2 production rate throughout the period of the test. The heart-rate monitor data suggest that a correction factor for PAL of 1.2 Â BMR should be applied. A bicarbonate recovery factor of 0.8 and a PAL of 1.2 were applied to breath PDR data from each test. The mean (s.d.) recovery of tracer across all tests (n ¼ 16) from corrected breath data plus urine data was 96.3 (713.5)%.
Discussion
We have shown that glycosyl [ 13 C]ureides are useful substrates for the noninvasive determination of OCTT. 13 C LU has been the focus of a number of studies of OCTT, but we have shown that 13 C GU is equally useful. The evidence in our study suggests that, following the action of small intestinal lactase on 13 C LU, 13 C GU is the substrate fermented in the large bowel when 13 C LU is consumed.
Predosing subjects with unlabelled glycosyl ureides produces an increase in the rate of fermentation of the labelled glycosyl ureides but has no effect on OCTT. This may be advantageous in a clinical setting where a definitive assessment of OCTT is required. Each breath test was undertaken at minimal physical activity and avoiding foodstuffs of higher 13 C abundance for 3 days prior to the test (Morrison et al, 2001) . Physical activity was kept at minimum in order to obtain an accurate estimation of CO 2 production rate (VCO 2 ). Furthermore, carbohydrate and lipid stores have been shown to have different 13 C abundance, with fat more depleted than carbohydrate (Schoeller et al, 1984) . Therefore, minimal activity conserves glycogen stores and limits fat oxidation. The test meal was chosen partly because it contained foodstuffs that were of low natural 13 C abundance and thus would be less likely to perturb basal 13 CO 2 . The minimal basal variation observed suggests that this test meal did not induce much variation in the expired 13 CO 2 abundance. Porridge also served as a suitable medium in which to take 13 C LU because it contains a component that is digested in the small intestine and a component that is fermented in the colon. Therefore, the transit of the substrate would be largely controlled by the physiological interaction between the test meal and the gut.
Each of the breath data sets in the study was analysed using curve-fitting techniques to quantify tracer recovery in breath CO 2 and also to determine OCTT. Other studies have based their determinations on the raw data alone. However, our curve-fitting approach allows a more accurate determination of parameters since calculations are based on the whole data set and are therefore less susceptible to local variations in the data. Data from tests 1 and 3, where no predosing was used, were better modelled (lower RMS) using the sum of two peaks (peak 1+peak 2 ¼ fitted model; Morrison et al, 1998) . This is purely a 'mathematical fix' that allows a model of this type to fit the data. The uncharacteristic shape of these data sets undoubtedly reflects the kinetics of bacterial hydrolysis of the sugar ureide bond, which has been reported to be carried out by Clostridium inocuum (Mohr et al, 1999) . Data sets with two distinct peaks (LU-induced 13 C LU) were also better modelled as the sum of two peaks.
In the present study, OCTT was defined as the time at which 13 C-breath enrichment had reached 10% of maximal enrichment. Other studies have defined OCTT as the point at which enrichment reaches 2.5 s.d.'s above the mean of the Figure 2 Profiles of 13 C recovery in breath CO 2 after test 1 (500 mg 13 C LU), test 2 (500 mg 13 C LU after predosing with LU), Test 3 (290 mg 13 C GU), and test 4 (500 mg 13 C LU after predosing with GU), in four subjects. Symbols indicate data measured by IRMS analysis of breath 13 CO 2 and solid lines indicate the curve fit to the data. Figure 3 Summary of calculated parameters (median values with 95% confidence intervals) for test 1 (500 mg 13 C LU), test 2 (500 mg 13 C LU after ingestion of 5 g unlabelled LU on the previous day), test 3 (290 mg 13 C GU) and test 4 (500 mg 13 C LU after 2.9 g unlabelled GU on the previous day) in four adult human volunteers. (Geypens et al, 1999) . The baseline in the present study was derived from the model as the one that allowed the best fit to the complete data set (lower RMS). There was considerable inter-and intra-individual variation in OCTT and this may reflect the sensitivity of this method and the day-to-day variability of transit times. 13 C LU and 13 C GU gave very similar OCTTs proving that 13 C GU does indeed reach the large intestine. Furthermore, the fact that the peak shapes were similar indicates that similar fermentation processes occur in the release of label from these substrates.
Glycosyl [
Although predosing with unlabelled LU or unlabelled GU appeared to shorten OCTT, this observation was not consistent within individuals. However, predosing increased the rate of appearance in the tracer in breath, quantified by the parameter T max ÀOCTT. The apparently lower value for T max in the predosed tests can also be explained by the change in peak shape, which exhibited a faster rise and hence shorter time to reach peak maximum. This choice of predosing regimen was based on information available in the literature (Wutzke et al, 1997 ). An immediate rise in breath 13 CO 2 may be desirable in a clinical test to unambiguously determine OCTT. The rate-limiting step, controlling the rate of 13 CO 2 appearance in breath, is the hydrolysis of the sugar ureide bond by bacterial enzymes. It is evident from this predosing regimen with LU or GU that it increases the rate of hydrolysis of the sugar ureide bond, although the mechanism leading to this rate increase is unclear. Predosing with LU appeared to introduce two distinct fermentation events in three out of four subjects, and predosing with GU only in one subject. This may be the result of partitioning of the dose either between the liquid and the solid phase of the meal or within different fractions of the meal, each arriving in the caecum at different times. Partitioning of the meal may be the result of different phases of gastric emptying (Siegal et al, 1988) , and we are undertaking further studies to investigate the effects of different gastric emptying patterns on 13 C LU fermentation. In each urine recovery profile, tracer appears earlier than in the breath. This suggests that, once absorbed, the tracer remains bound in a form that cannot be released by mammalian enzymes, otherwise an early peak would be seen in breath 13 CO 2 . This was not observed. We developed an assay for 13 C GU in urine, since it has been shown that brush-border lactase can hydrolyse the disaccharide bond in LU (to GU and galactose) as effectively as the disaccharide bond in lactose (Ruemmele et al, 1997) . The species incorporating most tracer correlated well with the R f of GU, indicating that the tracer is wholly incorporated in 13 C GU since little enrichment was found on the remainder of Figure 4 Profiles of 13 C recovery in urine after administration of 13 C-enriched glycosyl ureide after test 1 (500 mg 13 C LU), test 2 (500 mg 13 C LU after predosing with LU), test 3 (290 mg 13 C GU) and test 4 (500 mg 13 C LU after predosing with GU). C GU traverses the small intestine and appears in the urine unchanged. The fact that no breath 13 C recovery is observed when 13 C GU is absorbed (and excreted in urine) shows that once 13 C GU is absorbed it undergoes no further metabolism. The mechanism of absorption is unclear but is likely to be passive diffusion, comparable to that of other small water-soluble sugars, which have been used as 'probes' to measure passive intestinal permeability (Menzies, 1984) .
Urine was analysed for 13 C urea after the induction regimen, since one of the fermentation products of glycosyl ureides is thought to be urea, and it has been suggested that urea can traverse the colon intact (Moran & Jackson, 1990) . Increases in urinary urea 13 C enrichment occurred after an increase in breath 13 C enrichment (data not shown), and maximal urea 13 C enrichment was found to be less than that observed in breath CO 2 . Tracer recovery was generally under 3%. This compares well with other studies on urinary 13 C urea output, suggesting that urinary 13 C urea can all be attributed to biosynthesis in the body from a 13 C-enriched bicarbonate pool (Elia et al, 1995) . Urinary 13 C urea enrichment could not account for the total enrichment observed in any whole urine fraction. It is also unlikely that urinary 13 C urea could be the result of the absorption and excretion of any unbound 13 C urea in the substrate (ie contamination from residual 13 C urea in chemical synthesis). No urea was found when the substrate was incubated with urease in vitro (data not shown). Furthermore, one of the subjects has subsequently been identified as Helicobacter pylori positive, which would have resulted in the early appearance of breath 13 CO 2 (within 1 h) from the hydrolysis of unbound 13 C urea in the stomach (Graham et al, 1987) . This was not observed, further suggesting that there was no free 13 C urea present in the starting materials.
Urinary recovery of the tracer was similar for all tests, suggesting that the absorptive capacity from the small intestine is the limiting factor determining urinary recovery of tracer and not the efficacy of hydrolysis (of 13 C LU to 13 C GU) by brush-border lactase. The bacterial population in the colon also harbours high b-galactosidase activity, suggesting that any 13 C LU reaching the colon will be readily hydrolysed (Favier et al, 1997) . However, it is not known if cleavage of 13 C LU to 13 C GU is a necessary step in LU fermentation. Data from our in vitro experiments (not shown) show that LU is fermented even in the presence of high concentrations of the b-galactosidase inhibitor, phenylb-thiogalactoside. This would indicate that cleavage of the sugar urea bond is not dependent on prior hydrolysis of the disaccharide bond, and therefore many glycosyl ureide species of similar bond configuration may undergo similar metabolism. Breath PDR data were similar across all tests. All 13 Cenriched substrates metabolised in the body, which produce breath 13 CO 2 , release the tracer into the bicarbonate pool. This large carbon pool has the effect of slowing the transport of the tracer through the body, and indeed the tracer can be sequestrated irreversibly from this pool. Hence, correction factors were applied to the PDR data to account for sequestration of the tracer and also the effect of physical activity on VCO 2 . A factor of 1.2 Â BMR was used to correct PDR for PAL throughout the protocol since variations in physical activity undoubtedly affect VCO 2 and therefore breath PDR. Bicarbonate correction factors have been applied in many tracer studies to account for non-respiratory loss of carbon from the bicarbonate pool (Leijssen & Elia, 1996) . Based on the observed urine data and corrected breath PDR data, the partitioning of the tracer from 13 C LU metabolism can be described as follows: 13 C recovery ¼ 85% in breath+15% in urine 
